Published in Lab Invest on February 01, 1994
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A (1997) 2.53
Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res (2006) 2.49
Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest (1998) 1.90
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest (1998) 1.87
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int (2008) 1.85
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A (1994) 1.82
Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes (2010) 1.73
Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. Biochem J (2002) 1.70
Modification of the effect of glycemic status on aortic distensibility by age in the multi-ethnic study of atherosclerosis. Hypertension (2009) 1.69
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol (2002) 1.55
Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol (1998) 1.49
Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A (1996) 1.40
Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med (1995) 1.38
Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol (2001) 1.37
Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A (1998) 1.36
Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol (1997) 1.35
Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A (1996) 1.32
Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med (1995) 1.31
BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest (1996) 1.28
Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Invest Ophthalmol Vis Sci (2007) 1.17
Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol (2003) 1.17
Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet (2010) 1.15
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med (2007) 1.14
Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest (1997) 1.07
Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A (1995) 1.07
Methylglyoxal, an endogenous aldehyde, crosslinks DNA polymerase and the substrate DNA. Nucleic Acids Res (2001) 1.07
The effect of the microscopic and nanoscale structure on bone fragility. Osteoporos Int (2008) 1.07
Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes (2011) 1.06
Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol (2011) 1.02
Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol (2001) 1.01
Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest (1997) 1.01
Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med (1997) 1.01
Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev (2011) 1.00
Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem (2010) 0.97
The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration. Am J Pathol (2004) 0.96
Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res (2007) 0.94
The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes. Front Endocrinol (Lausanne) (2012) 0.94
Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol (2005) 0.94
Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats. Dig Dis Sci (2011) 0.92
Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp Mol Med (2008) 0.92
Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem J (2001) 0.92
Advanced glycation end products in human optic nerve head. Br J Ophthalmol (2001) 0.92
Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care (2012) 0.91
Tendon repair is compromised in a high fat diet-induced mouse model of obesity and type 2 diabetes. PLoS One (2014) 0.91
Effects of advanced glycosylation endproducts on perlecan core protein of glomerular epithelium. Pediatr Nephrol (2004) 0.91
Advanced glycation of type I collagen and fibronectin modifies periodontal cell behavior. J Periodontol (2008) 0.90
Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest (1996) 0.90
Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. Am J Pathol (2002) 0.89
Lens epithelial cell apoptosis initiates diabetic cataractogenesis in the Zucker diabetic fatty rat. Graefes Arch Clin Exp Ophthalmol (2010) 0.89
Glycated albumin: an overview of the In Vitro models of an In Vivo potential disease marker. J Diabetes Metab Disord (2014) 0.88
Kaempferol modulates pro-inflammatory NF-kappaB activation by suppressing advanced glycation endproducts-induced NADPH oxidase. Age (Dordr) (2010) 0.88
Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J (1999) 0.87
Involvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathy. Graefes Arch Clin Exp Ophthalmol (2010) 0.86
N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status. J Clin Biochem Nutr (2008) 0.85
Oxidative stress as a mechanism of added sugar-induced cardiovascular disease. Int J Angiol (2014) 0.85
Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol (2009) 0.84
Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition. Exp Mol Med (2011) 0.84
Silver nanoparticles as real topical bullets for wound healing. J Am Coll Clin Wound Spec (2012) 0.84
Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev (2010) 0.82
Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. Graefes Arch Clin Exp Ophthalmol (2003) 0.82
Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol (2006) 0.82
Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP. Int J Clin Exp Pathol (2013) 0.81
Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid Med Cell Longev (2016) 0.81
Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals. Clin Exp Immunol (1998) 0.81
Secondary hyperparathyroidism and target organs in chronic kidney disease. Hippokratia (2011) 0.80
Aminoguanidine prevents age-related aortic stiffening in Fisher 344 rats: aortic impedance analysis. Br J Pharmacol (2003) 0.80
From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm (Vienna) (2006) 0.80
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med (1998) 0.79
The Antioxidant Capacity and Anti-diabetic Effect of Boswellia serrata Triana and Planch Aqueous Extract in Fertile Female Diabetic Rats and the Possible Effects on Reproduction and Histological Changes in the Liver and Kidneys. Jundishapur J Nat Pharm Prod (2012) 0.79
The effects of combined treatment of antioxidants on the liver injury in STZ diabetic rats. Dig Dis Sci (2008) 0.79
Antiaging effect of pine pollen in human diploid fibroblasts and in a mouse model induced by D-galactose. Oxid Med Cell Longev (2012) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Is the present cut-point to define type 2 diabetes appropriate in Latin-Americans? World J Diabetes (2014) 0.78
The Effects of Low-Power Laser Irradiation on Inflammation and Apoptosis in Submandibular Glands of Diabetes-Induced Rats. PLoS One (2017) 0.77
Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses. Clin Exp Immunol (2015) 0.77
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci U S A (1998) 0.77
Noninvasive skin fluorescence spectroscopy for diabetes screening. J Diabetes Sci Technol (2013) 0.77
Advanced glycation end products and diabetic retinopathy. J Ocul Biol Dis Infor (2013) 0.77
RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells. PLoS One (2016) 0.77
Regulation of glomerular endothelial cell proteoglycans by glucose. J Korean Med Sci (2004) 0.77
Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan. PLoS One (2015) 0.77
Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. PLoS One (2013) 0.77
Anti-Apoptotic and Pro-Survival Effect of Alpinate Oxyphyllae Fructus (AOF) in a d-Galactose-Induced Aging Heart. Int J Mol Sci (2016) 0.77
KIOM-79 Prevents Lens Epithelial Cell Apoptosis and Lens Opacification in Zucker Diabetic Fatty Rats. Evid Based Complement Alternat Med (2010) 0.76
Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. J Ophthalmol (2010) 0.76
Abnormal stress-related measures of arterial stiffness in middle-aged and elderly men and women with impaired fasting glucose at risk for a first episode of symptomatic heart failure. J Am Heart Assoc (2015) 0.76
RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage. Oxid Med Cell Longev (2016) 0.76
The breakdown of preformed peritoneal advanced glycation end products by intraperitoneal alagebrium. J Korean Med Sci (2009) 0.75
Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis (2017) 0.75
Measurement of Lens Autofluorescence for Diabetes Screening. J Diabetes Sci Technol (2014) 0.75
Abnormal levels of age-elastin derived peptides in sera of diabetic patients with arterial hypertension. Cent Eur J Immunol (2014) 0.75
Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol (2001) 7.40
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 5.55
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 3.89
An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 3.79
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med (1997) 2.98
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem (1999) 2.60
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A (1997) 2.53
The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A (1997) 2.36
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun (2002) 2.21
The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med (1996) 2.21
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 2.17
An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med (1999) 2.10
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene (2007) 2.08
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med (1996) 1.99
Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1996) 1.95
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J (2001) 1.91
Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun (1998) 1.87
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol (1997) 1.86
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A (2005) 1.79
De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res (2000) 1.78
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A (1999) 1.74
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene (2006) 1.68
Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet (1996) 1.63
Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol (1998) 1.63
Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol (1993) 1.60
Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med (1995) 1.55
Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. Proc Natl Acad Sci U S A (1984) 1.55
Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet (1994) 1.55
Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci U S A (1998) 1.51
Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest (1998) 1.46
Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun (2007) 1.43
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol (1996) 1.40
Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry (1997) 1.40
Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (1992) 1.40
Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum (1998) 1.39
Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int (1994) 1.38
Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol (2000) 1.38
Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol (1997) 1.37
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun (2000) 1.37
Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol (1997) 1.35
Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol (1995) 1.35
Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A (1996) 1.32
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia (2006) 1.32
An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med (1995) 1.31
Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol (2001) 1.29
Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1997) 1.28
DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states. J Infect Dis (1993) 1.27
Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) (2002) 1.27
Peripheral blood fibrocytes: mesenchymal precursor cells and the pathogenesis of fibrosis. Curr Rheumatol Rep (2000) 1.25
Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes (1995) 1.25
Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med (Berl) (1998) 1.24
Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proc Natl Acad Sci U S A (1998) 1.24
Identification of N2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry (1995) 1.23
Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol (2001) 1.22
Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int (2000) 1.20
The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest (2000) 1.19
Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest (1992) 1.18
Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today (1997) 1.17
Application of DNA amplification to pneumocystosis: presence of serum Pneumocystis carinii DNA during human and experimentally induced Pneumocystis carinii pneumonia. J Exp Med (1992) 1.17
Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.15
Role of macrophage migration inhibitory factor in the regulation of the immune response. Adv Immunol (1997) 1.12
Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. Biochem Soc Trans (1997) 1.11
MIF expression in the rat brain: implications for neuronal function. Mol Med (1998) 1.10
Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology (2001) 1.09
Formation of covalent adducts between cortisol and 16 alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci U S A (1982) 1.09
Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol (2000) 1.09
Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci (1998) 1.09
Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes (1996) 1.09
Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism (1997) 1.08
Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med (1998) 1.07
Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem (1998) 1.06
Identification and characterization of a homologue of the pro-inflammatory cytokine Macrophage Migration Inhibitory Factor in the tick, Amblyomma americanum. Insect Mol Biol (2001) 1.05
The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng (1996) 1.05
Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm (1997) 1.04
Modification of DNA by glucose 6-phosphate induces DNA rearrangements in an Escherichia coli plasmid. Proc Natl Acad Sci U S A (1985) 1.04
Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest (1984) 1.03
Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med (1997) 1.01
Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand) (1998) 1.01
Detection of an advanced glycosylation product bound to protein in situ. J Biol Chem (1985) 1.00
Neuroendocrine properties of macrophage migration inhibitory factor (MIF). Immunol Cell Biol (2001) 1.00
Comparative analysis of DNA mutations in lacI transgenic mice with age. FASEB J (1994) 1.00
Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int (2000) 0.98
Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine (2013) 0.98
Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging (1997) 0.98
Rapidly progressive ('crescentic') glomerulonephritis and monoclonal gammapathies. Nephron (1984) 0.98
Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance. Diabetologia (2002) 0.97